-$0.79 EPS Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter

Brokerages forecast that Aquestive Therapeutics Inc (NASDAQ:AQST) will announce earnings of ($0.79) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aquestive Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.74). Aquestive Therapeutics reported earnings per share of ($0.49) in the same quarter last year, which suggests a negative year over year growth rate of 61.2%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Aquestive Therapeutics will report full year earnings of ($2.97) per share for the current financial year, with EPS estimates ranging from ($3.10) to ($2.83). For the next year, analysts forecast that the firm will post earnings of ($2.50) per share, with EPS estimates ranging from ($2.97) to ($2.03). Zacks’ EPS averages are an average based on a survey of research analysts that cover Aquestive Therapeutics.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.15). The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $10.46 million. Aquestive Therapeutics had a negative return on equity of 8,682.29% and a negative net margin of 119.15%.

AQST has been the subject of a number of research reports. Wedbush set a $31.00 target price on shares of Aquestive Therapeutics and gave the stock a “buy” rating in a research note on Friday, July 5th. HC Wainwright initiated coverage on shares of Aquestive Therapeutics in a research note on Monday, April 22nd. They set a “buy” rating and a $10.00 target price for the company. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 12th. Finally, ValuEngine upgraded shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $19.54.

Institutional investors have recently modified their holdings of the business. Spark Investment Management LLC acquired a new stake in Aquestive Therapeutics in the 1st quarter worth about $80,000. Bank of New York Mellon Corp acquired a new stake in Aquestive Therapeutics in the 4th quarter worth about $108,000. Morgan Stanley raised its stake in Aquestive Therapeutics by 706.1% in the 2nd quarter. Morgan Stanley now owns 17,323 shares of the company’s stock worth $73,000 after purchasing an additional 15,174 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Aquestive Therapeutics by 728.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock worth $93,000 after purchasing an additional 20,014 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter worth about $145,000. Institutional investors and hedge funds own 66.42% of the company’s stock.

Shares of NASDAQ AQST traded up $0.29 during mid-day trading on Monday, reaching $3.81. 24,300 shares of the company were exchanged, compared to its average volume of 71,090. The company’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $5.31. The company has a quick ratio of 1.40, a current ratio of 1.59 and a debt-to-equity ratio of 4.23. The stock has a market capitalization of $95.36 million and a P/E ratio of -1.36. Aquestive Therapeutics has a twelve month low of $2.96 and a twelve month high of $20.70.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Recommended Story: What is a death cross?

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.